blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3921327

EP3921327 - GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2024
Database last updated on 03.05.2025
FormerThe patent has been granted
Status updated on  03.03.2023
FormerGrant of patent is intended
Status updated on  04.10.2022
FormerRequest for examination was made
Status updated on  12.11.2021
FormerThe international publication has been made
Status updated on  14.08.2020
Formerunknown
Status updated on  16.03.2020
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): BG		published on 18.12.2024  [2024/51]
Applicant(s)For all designated states
Ardelyx, Inc.
34175 Ardenwood Blvd., Suite 200
Fremont, California 94555 / US
[2021/50]
Inventor(s)01 / DRAGOLI, Dean
c/o Ardelyx, Inc. 34175 Ardenwood Blvd Suite 200
Fremont, California 94555 / US
02 / LUEHR, Gary
c/o Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200
Fremont, California 94555 / US
03 / CHEN, Tao
c/o Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200
Fremont, California 94555 / US
04 / LEWIS, Jason
c/o Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200
Fremont, California 94555 / US
05 / LEADBETTER, Michael
c/o Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200
Fremont, California 94555 / US
 [2023/14]
Former [2021/50]01 / DRAGOLI, Dean
Fremont, California 94555 / US
02 / LUEHR, Gary
Fremont, California 94555 / US
03 / CHEN, Tao
Fremont, California 94555 / US
04 / LEWIS, Jason
Fremont, California 94555 / US
05 / LEADBETTER, Michael
Fremont, California 94555 / US
Representative(s)Grund, Martin, et al
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[2023/14]
Former [2021/50]Grund, Martin, et al
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Application number, filing date20709101.806.02.2020
[2021/50]
WO2020US17077
Priority number, dateUS201962802210P07.02.2019         Original published format: US 201962802210 P
[2021/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020163642
Date:13.08.2020
Language:EN
[2020/33]
Type: A1 Application with search report 
No.:EP3921327
Date:15.12.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2020 takes the place of the publication of the European patent application.
[2021/50]
Type: B1 Patent specification 
No.:EP3921327
Date:05.04.2023
Language:EN
[2023/14]
Search report(s)International search report - published on:EP13.08.2020
ClassificationIPC:C07J63/00, A61K31/56, A61P5/40
[2021/50]
CPC:
C07J63/008 (EP,IL,KR,US); A61K31/56 (KR,US); A61K31/58 (US);
A61P3/12 (US); A61P5/40 (EP,KR,US); A61P9/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/50]
Extension statesBA02.09.2021
ME02.09.2021
Validation statesKH02.09.2021
MA02.09.2021
MD02.09.2021
TN02.09.2021
TitleGerman:GLYCYRRHETINSÄUREDERIVATE ZUR BEHANDLUNG VON HYPERKALIÄMIE[2021/50]
English:GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA[2021/50]
French:DÉRIVÉS D'ACIDE GLYCYRRHÉTINIQUE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'HYPERKALIÉMIE[2021/50]
Entry into regional phase02.09.2021National basic fee paid 
02.09.2021Designation fee(s) paid 
02.09.2021Examination fee paid 
Examination procedure02.09.2021Examination requested  [2021/50]
02.09.2021Date on which the examining division has become responsible
23.03.2022Amendment by applicant (claims and/or description)
05.10.2022Communication of intention to grant the patent
10.02.2023Fee for grant paid
10.02.2023Fee for publishing/printing paid
10.02.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23164821.3  / EP4234016
Opposition(s)08.01.2024No opposition filed within time limit [2024/11]
Fees paidRenewal fee
25.02.2022Renewal fee patent year 03
27.02.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.04.2023
AT05.04.2023
BG05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SI05.04.2023
SK05.04.2023
SM05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
[2024/51]
Former [2024/45]AL05.04.2023
AT05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SI05.04.2023
SK05.04.2023
SM05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/26]AL05.04.2023
AT05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SI05.04.2023
SK05.04.2023
SM05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/10]AL05.04.2023
AT05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SK05.04.2023
SM05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/08]AL05.04.2023
AT05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
SK05.04.2023
SM05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/03]AL05.04.2023
AT05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/01]AL05.04.2023
AT05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/51]AL05.04.2023
AT05.04.2023
HR05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/50]AL05.04.2023
AT05.04.2023
NL05.04.2023
PL05.04.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/48]AT05.04.2023
NL05.04.2023
PT07.08.2023
Former [2023/46]NL05.04.2023
PT07.08.2023
Former [2023/43]NL05.04.2023
Cited inInternational search[A]US2015218206  (YOON YEO-HONG [KR]);
by applicantUS4278793
 WO9426709
 CA2177007
 EP0744397
 WO9724113
 CA2241531
 US5824691
 US5866610
 US6005010
 WO0121582
 CA2387529
 WO0172742
 WO0220496
 WO0224637
 US6399824
 WO03051866
 WO03055490
 US2004039001
 US6703405
 US6736705
 US6737423
 US2004113396
 US2004224965
 US2005020612
 US2005054705
 US6887870
 US2005113396
 US6911453
 US2005244367
 US2007135383
 US2007135385
 US2007225323
 US2007270414
 US7326705
 US2008194621
 WO2010078449
 WO2014029983
 WO2014029984
 WO2016111855
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.